Point of Care (PoC) Molecular Diagnostics Market Size By Technology [Polymerase Chain Reaction (Real Time PCR, DNA/RNA Purification), In Situ Hybridization, Chips and Microarrays, Mass Spectrometry, Sequencing, Isothermal Amplification, Others], By Infectious Diseases (MRSA, Clostridium difficile, Vancomycin-resistant Enterococci, Carbapenem-Resistant Bacteria Testing, Flu, Respiratory Syncytial Virus, Candida, Tuberculosis and Drug-resistant TB, Meningitis, Gastro-intestinal Panel Testing, Chlamydia, Gonorrhea, HIV , Hepatitis C, Hepatitis B, HPV, Syphilis, Others), Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, France, Spain, Italy, Russia, Japan, China, India, South Korea, Malaysia, Thailand, Vietnam, Philippines, Australia, Brazil, Argentina, Mexico, South Africa, Nigeria, Egypt, Morocco, Saudi Arabia, UAE), Application Potential, Price Trends, Competitive Market Share & Forecast, 2017 – 2024

Industry Trends

Point of Care (PoC) Molecular Diagnostics Market size was over USD 1 billion in 2016, with growth forecast over 9% CAGR from 2017 to 2024.
 

U.S. Point of Care (PoC) Molecular Diagnostics Market size, By Infectious Diseases, 2013-2024 (USD Million)

Get more details on this report - Request Free Sample PDF
 

Point of Care (PoC) molecular diagnostics market is poised to witness robust growth over the forecast period. Increasing infectious diseases incidence coupled with growing public awareness levels pertaining to pre-disease detection to control its occurrence will drive PoC molecular diagnostics market growth.
 

Quick and precise detection of causative agents is of utmost importance in infectious disease emergency cases as the inaccuracy in disease detection leads to incorrect treatment which escalates disease spreading risk. Point of care molecular diagnostic assays permit the timely detection of the causative agent enabling effective disease control.
 

Several organizations such as Foundation for Innovative New Diagnostics conduct various initiatives and programs for creating awareness regarding pre-disease detection which will augment industry expansion in the coming years.
 

Increasing research and development funding in this field serves as a high impact rendering factor. Governments and private entities provide funds for development of cost effective solutions to cater to the growing consumer demand.
 

Advancements in the areas of DNA sequencing and analysis will enable faster and accurate detection of causative agents. Such technological advances will further propel PoC molecular diagnostics market growth. 
 

However, long time required for developing molecular diagnostics hampers industry growth. The development process involves several stages such as research, prototype designing, testing and finally pre- and post-market procedures which make it lengthy. Existence of complex regulatory procedures further restrain expansion.
 

Point of Care (PoC) Molecular Diagnostics Market, By Technology

Polymerase Chain Reaction (PCR) technology held the largest share in 2016 and is slated to witness rapid growth over the coming years owing to its extended application and improved precision and reproducibility. Growing incidence of infectious disease and genetic disorders coupled with increase in public-private investment in PCR oriented research will propel segment growth.
 

Chips and microarrays will witness significant growth during the forecast period as they are at the forefront of the ongoing revolution in life science and molecular biology.
 

Point of Care (PoC) Molecular Diagnostics Market, By Infectious Diseases

Flu molecular diagnostics market held significant share in 2016. The segment is poised to grow at a rapid pace owing to the increase global burden of seasonal influenza. Flu prevalence is growing among the ageing population, new born children and individuals afflicted with certain chronic conditions who have a higher susceptibility to the disease. Increasing availability of screening tests for A and B virus infectious should further stimulate Flu PoC test demand.
 

Candida molecular diagnostics market will witness profitable growth as it is one of the most serious health acquired infection in immuno-compromised individuals across the globe. Ongoing advancements in Candida detection focused on the development of portable point of care tests which are compact and simple to use for rapid and precise testing will drive segment growth. Firms are engaged in rigorous research and development for devising automatic platforms that automatically performs all the processes such as cell lysis, DNA / RNA extraction, purification along with detection.
 

Hepatitis B infection is also amongst the most important global health problems affecting large population pool. Laboratory detection of HBV is based on immune detection of HBsAg. However, the problem of HBsAg non-detection owing to diagnostic escape mutations in the isotopes or low antigen levels have greatly emphasized importance of molecular biology tools for virus detection stimulating the demand.
 

Point of Care (PoC) Molecular Diagnostics Market, By Region

U.S. point of care molecular diagnostics market held significant revenue share in 2016. Growing infectious disease incidence leading to huge healthcare costs and increasing focus on preventive care to reduce the economic burden are propelling the PoC molecular diagnostics market size. Increasing demand for fast and portable tests along with rising diagnostics adoption rate for use in and outside hospital settings serves as a highly influential factor driving industry growth.
 

South Africa point of care molecular diagnostics market presents a lucrative future opportunity owing to the increasing focus on curtailment of HIV and Tuberculosis.
 

Competitive Market Share

At present, few major players such as Roche, Abbott and Danaher dominate the PoC molecular diagnostics market. Other prominent industry participants include Bayer, BioMerieux, Bio-Rad Laboratories and Sysmex. The industry rivalry is set to intensify in the near future as an increasing number of manufacturers are entering this particular nice.
 

Existing industry players are engaged in rigorous R&D activities to develop solutions for treating new diseases. These companies resort to various strategies such as acquisitions and new product development to increase their market presence. For instance, in September 2017, Abbott acquired Alere to strengthen its point of care business.
 

Point of Care (PoC) Molecular Diagnostics Industry Background
 

Get more details on this report - Request Free Sample PDF
 

The industry is witnessing rapid technological advancements owing to the ongoing R&D activities of companies as well as various research institutes. These entities are focusing their efforts on coming up with solutions that require comparatively lower amounts of sample and minimal user intervention. The emergence of new disease conditions and surge in existing infectious disease incidence especially in developing countries presents a lucrative future opportunity for the operating firms.  

What Information does this report contain?